Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories

The Clinical and Laboratory Standards Institute (CLSI) has revised several breakpoints since 2010 for bacteria that grow aerobically. In 2019, these revisions include changes to the ciprofloxacin and levofloxacin breakpoints for the and , daptomycin breakpoints for spp., and ceftaroline breakpoints...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical microbiology 2019-06, Vol.57 (6)
Main Authors: Humphries, Romney M, Abbott, April N, Hindler, Janet A
Format: Article
Language:English
Subjects:
Minireview
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Clinical and Laboratory Standards Institute (CLSI) has revised several breakpoints since 2010 for bacteria that grow aerobically. In 2019, these revisions include changes to the ciprofloxacin and levofloxacin breakpoints for the and , daptomycin breakpoints for spp., and ceftaroline breakpoints for Implementation of the revisions is a challenge for all laboratories, as not all systems have FDA clearance for the revised (current) breakpoints, compounded by the need for laboratories to perform validation studies and to make updates to laboratory information system/electronic medical record builds in the setting of limited information technology infrastructure. This minireview describes the breakpoint revisions in the M100 supplement since 2010 and strategies for the laboratory on how to best adopt these in clinical testing.
ISSN:0095-1137
1098-660X
DOI:10.1128/JCM.00203-19